Abstract
The hippocampus consists of anatomically and functionally distinct subfields that may be differentially involved in the pathophysiology of bipolar disorder (BD). Here we, the Enhancing NeuroImaging Genetics through Meta-Analysis Bipolar Disorder workinggroup, study hippocampal subfield volumetry in BD. T1-weighted magnetic resonance imaging scans from 4,698 individuals (BD = 1,472, healthy controls [HC] = 3,226) from 23 sites worldwide were processed with FreeSurfer. We used linear mixed-effects models and mega-analysis to investigate differences in hippocampal subfield volumes between BD and HC, followed by analyses of clinical characteristics and medication use. BD showed significantly smaller volumes of the whole hippocampus (Cohen'sd = -0.20), cornu ammonis (CA)1 (d = -0.18), CA2/3 (d = -0.11), CA4 (d = -0.19), molecular layer (d = -0.21), granule cell layer of dentate gyrus (d = -0.21), hippocampal tail (d = -0.10), subiculum (d = -0.15), presubiculum (d = -0.18), and hippocampal amygdala transition area (d = -0.17) compared to HC. Lithium users did not show volume differences compared to HC, while non-users did. Antipsychotics or antiepileptic use was associated with smaller volumes. In this largest study of hippocampal subfields in BD to date, we show widespread reductions in nine of 12 subfields studied. The associations were modulated by medication use and specifically the lack of differences between lithium users and HC supports a possible protective role of lithium in BD.
Original language | English |
---|---|
Pages (from-to) | 385-398 |
Number of pages | 14 |
Journal | Human Brain Mapping |
Volume | 43 |
Issue number | 1 |
Early online date | 19 Oct 2020 |
DOIs | |
Publication status | Published - Jan 2022 |
Keywords
- ATLAS
- BRAIN
- CELL-PROLIFERATION
- DENTATE GYRUS
- HALOPERIDOL
- INTERNEURONS
- LITHIUM-TREATED PATIENTS
- MRI
- SCHIZOPHRENIA
- SEGMENTATION
- bipolar disorder subtype
- hippocampus
- large-scale
- lithium
- psychosis
- structural brain MRI
Access to Document
- 10.1002/hbm.25249Licence: CC BY
Fingerprint
Dive into the research topics of 'In vivo hippocampal subfield volumes in bipolar disorder-A mega-analysis from The Enhancing Neuro Imaging Genetics throughMeta-AnalysisBipolar Disorder Working Group'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Human Brain Mapping, Vol. 43, No. 1, 01.2022, p. 385-398.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - In vivo hippocampal subfield volumes in bipolar disorder-A mega-analysis from The Enhancing Neuro Imaging Genetics throughMeta-AnalysisBipolar Disorder Working Group
AU - Haukvik, Unn K.
AU - Gurholt, Tiril P.
AU - Nerland, Stener
AU - Elvsashagen, Torbjorn
AU - Akudjedu, Theophilus N.
AU - Alda, Martin
AU - Alnaes, Dag
AU - Alonso-Lana, Silvia
AU - Bauer, Jochen
AU - Baune, Bernhard T.
AU - Benedetti, Francesco
AU - Berk, Michael
AU - Bettella, Francesco
AU - Boen, Erlend
AU - Bonnin, Caterina M.
AU - Brambilla, Paolo
AU - Canales-Rodriguez, Erick J.
AU - Cannon, Dara M.
AU - Caseras, Xavier
AU - Dandash, Orwa
AU - Dannlowski, Udo
AU - Delvecchio, Giuseppe
AU - Diaz-Zuluaga, Ana M.
AU - Erp, Theo G. M.
AU - Fatjo-Vilas, Mar
AU - Foley, Sonya F.
AU - Foerster, Katharina
AU - Fullerton, Janice M.
AU - Goikolea, Jose M.
AU - Grotegerd, Dominik
AU - Gruber, Oliver
AU - Haarman, Bartholomeus C. M.
AU - Haatveit, Beathe
AU - Hajek, Tomas
AU - Hallahan, Brian
AU - Harris, Mathew
AU - Hawkins, Emma L.
AU - Howells, Fleur M.
AU - Huelsmann, Carina
AU - Jahanshad, Neda
AU - Jorgensen, Kjetil N.
AU - Kircher, Tilo
AU - Kraemer, Bernd
AU - Krug, Axel
AU - Kuplicki, Rayus
AU - Lagerberg, Trine
AU - Lancaster, Thomas M.
AU - Lenroot, Rhoshel K.
AU - Lonning, Vera
AU - Meer, Dennis
AU - ENIGMA Bipolar Disorder Working Group
N1 - Funding Information: Instituto de Salud Carlos III, FEDER Funds/European Regional Development Fund, Grant/Award Numbers: PI19/00394, CPII19/00009; Departament de Salut de la Generalitat de Catalunya, Grant/Award Number: SLT002/16/00331; FAPESP; Singapore Bioimaging Consortium, Grant/Award Number: RP C‐009/2006; NWO/ZonMW VENI‐Grant, Grant/Award Number: 016.126.059; Netherlands Organization for Health Research and Development (ZonMw), Program Mental Health, Education of Investigators in Mental Health, Grant/Award Number: 100‐002‐034; NIGMS, Grant/Award Number: P20GM121312; NIMH, Grant/Award Number: R21MH113871; William K Warren Foundation; National Research Foundation, South Africa and University Research Committee, University of Cape Town; Wellcome Trust Strategic Award, Grant/Award Number: 104036/Z/14/Z; European Community's Seventh Framework Program, Grant/Award Number: FP7/2007‐2013; Lansdowne Foundation; Australian National Medical and Health Research Council, Grant/Award Numbers: 1063960, 1066177, 1037196; Ebbe Frøland Foundation; Oslo University Hospital—Rikshospitalet; PRISMA UT—Colciencias and Convocatoria Programática Ciencias de la Salud 2014‐2015 by CODI‐Universidad de Antioquia U de A; Interdisciplinary Center for Clinical Research (IZKF) of the Medical Faculty of Münster, Grant/Award Numbers: SEED11/18, Dan3/012/17; German Research Foundation, Grant/Award Numbers: KO 4291/3‐1, NE 2254/1‐2, KR 3822/7‐2, KR 3822/5‐1, KI 588/14‐2, KI 588/14‐1, DA 1151/5‐2, DA 1151/5‐1, FOR2107, SFB‐TRR58; Bipolar Disorder Research Network (BDRN), Grant/Award Number: 17319; Italian Ministry of Health, Grant/Award Numbers: RF‐2011‐02350980, RF‐2016‐02364582; European Regional Development Fund/European Social Fund, Grant/Award Numbers: PI18/00877, PI18/00810, CD18/00029, CD16/00264, MSII16/00018; Instituto de Salud Carlos III; Generalitat de Catalunya, Grant/Award Number: 2017SGR1271; National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship, Grant/Award Numbers: APP1156072, 1059660; AstraZeneca; Brain & Behavior Research Foundation; Dalhousie Clinical Research Scholarship; Nova Scotia Health Research Foundation; Canadian Institutes of Health Research, Grant/Award Numbers: 142255, 106469, 103703; Health Research Board, Grant/Award Number: HRA‐POR‐324; South‐Eastern Norway Regional Health Authority, Grant/Award Numbers: 2014097, 2017112, 2017097; KG Jebsen Stiftelsen; The Research Council of Norway, Grant/Award Numbers: 288083, 250358, 213700, 223273; National Institutes of Health (NIH), Grant/Award Numbers: R01MH116147, U54EB020403, 5T32MH073526, T32AG058507, R01AG059874, R01MH117601, U54 EB020403 Funding information Funding Information: : NIH grant U54 EB020403 from the Big Data to Knowledge (BD2K) Program; R01MH117601, R01AG059874; T32AG058507; 5T32MH073526. : The Research Council of Norway (grant numbers 223273, 213700, 250358, 288083); KG Jebsen Stiftelsen; South‐Eastern Norway Regional Health Authority (grant number 2017097; 2017112). : Funded by the Health Research Board (HRA‐POR‐324) awarded to Dara M. Cannon, PhD. : The Halifax studies were supported by funding from the Canadian Institutes of Health Research (103703, 106469, and 142255), Nova Scotia Health Research Foundation, Dalhousie Clinical Research Scholarship to T. Hajek, Brain & Behavior Research Foundation (formerly NARSAD); 2007 Young Investigator and 2015 Independent Investigator Awards to T. Hajek. : Supported by an unrestricted grant from AstraZeneca. MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). : Generalitat de Catalunya: 2017SGR1271; Instituto de Salud Carlos III (co‐funded by the European Regional Development Fund/European Social Fund): MSII16/00018, CD16/00264, CD18/00029, PI18/00810, and PI18/00877. : PB was partially supported by a grant from the Italian Ministry of Health (RF‐2016‐02364582). : Recruitment was supported by the National Centre for Mental Health (NCMH) funded by the Health and Care Research Wales and the Bipolar Disorder Research Network (BDRN), and funded through seedcorn funding from Cardiff University and a NARSAD Young Investigator Award to XC (ref. 17319). : Funded by the German Research Foundation (SFB‐TRR58, Project C09 to UD) and the Interdisciplinary Center for Clinical Research (IZKF) of the Medical Faculty of Münster (grant Dan3/012/17 to UD and grant SEED11/18 to NO). : Funded by the German Research Foundation (DFG), Udo Dannlowski (co‐speaker FOR2107; DA 1151/5‐1, DA 1151/5‐2). : Funded by the German Research Foundation (DFG), Tilo Kircher (speaker FOR2107; DFG grant numbers KI 588/14‐1, KI 588/14‐2), Axel Krug (KR 3822/5‐1, KR 3822/7‐2), Igor Nenadic (NE 2254/1‐2), Carsten Konrad (KO 4291/3‐1). : Supported by PRISMA UT—Colciencias and Convocatoria Programática Ciencias de la Salud 2014‐2015 by CODI‐Universidad de Antioquia U de A. : The Research Council of Norway; South‐Eastern Norway Regional Health Authority (2014097); Oslo University Hospital—Rikshospitalet; the Ebbe Frøland Foundation; a research grant from Mrs. Throne‐Holst. : Supported by the Australian National Medical and Health Research Council (Program Grant 1037196; Project Grants 1066177 and 1063960), and the Lansdowne Foundation. We also acknowledge the Janette Mary O'Neil Research Fellowship (to JMF). : The CliNG study sample was partially supported by the Deutsche Forschungsgemeinschaft (DFG) via the Clinical Research Group 241 “Genotype‐phenotype relationships and neurobiology of the longitudinal course of psychosis,” TP2 (PI Gruber; http://www.kfo241.de/ GR 1950/5‐1). : Funded by EU‐FP7‐HEALTH‐222963 “MOODINFLAME” and EU‐FP7‐PEOPLE‐286334 “PSYCHAID”. : Supported by IMAGEMEND, which received funding from the European Community's Seventh Framework Program (FP7/2007‐2013) under grant agreement no. 602450. This article reflects only the author's views and the European Union is not liable for any use that may be made of the information contained therein. Also supported by a Wellcome Trust Strategic Award 104036/Z/14/Z. : Supported by the National Research Foundation, South Africa and University Research Committee, University of Cape Town. : Supported by the William K Warren Foundation, the NIMH: R21MH113871, and the NIGMS: P20GM121312. : Received no specific grant from any funding agency, commercial or not‐for‐profit sectors. : Netherlands Organization for Health Research and Development (ZonMw), Program Mental Health, Education of Investigators in Mental Health (OOG; #100‐002‐034). NWO/ZonMW VENI‐Grant #016.126.059. : Funded by the Singapore Bioimaging Consortium (RP C‐009/2006) research grant awarded to Kang Sim. : FAPESP. : FIS, PERIS, ISCIII. PERIS grant from Departament de Salut de la Generalitat de Catalunya (SLT002/16/00331). Miguel Servet II Research Contract (CPII19/00009) and Research Project (PI19/00394) from Instituto de Salud Carlos III, FEDER Funds/European Regional Development Fund—a way to build Europe. : Dr. van Erp reports funding by U54EB020403 and R01MH116147. : Italian Ministry of Health grant RF‐2011‐02350980. ENIGMA Core TOP NUI Galway Dalhousie Deakin University FIDMAG Milan Cardiff MNC Muenster Marburg Medellín/GIPSI OUS Sydney/UNSW CLING/HMS Groningen BFS Cape Town LIBR Frankfurt Amsterdam Singapore USP 3T Hospital Clínic Hippocampal Subfield Protocol Development Team Milan‐2 Funding Information: MB: was supported by an unrestricted grant from AstraZeneca; TE, UFM, EB: has received speaker's fees from Lundbeck AS, and Janssen Cilag; NJ, PMT: MPI of a research grant from Biogen, Inc. for work unrelated to the contents of this manuscript; CRKC: is partially funded by a Biogen Grant (to NJ and PMT) for research unrelated to the contents of this manuscript. DJS: has received research grants and/or honoraria from Lundbeck and Sun; OAA: has received speaker's honorarium from Lundbeck, and is a consultant to HealthLytix. AMM: has received research support from Eli Lilly, Janssen, and the Sackler Foundation, and has also received speaker fees from Illumina and Janssen. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: © 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.
PY - 2022/1
Y1 - 2022/1
N2 - The hippocampus consists of anatomically and functionally distinct subfields that may be differentially involved in the pathophysiology of bipolar disorder (BD). Here we, the Enhancing NeuroImaging Genetics through Meta-Analysis Bipolar Disorder workinggroup, study hippocampal subfield volumetry in BD. T1-weighted magnetic resonance imaging scans from 4,698 individuals (BD = 1,472, healthy controls [HC] = 3,226) from 23 sites worldwide were processed with FreeSurfer. We used linear mixed-effects models and mega-analysis to investigate differences in hippocampal subfield volumes between BD and HC, followed by analyses of clinical characteristics and medication use. BD showed significantly smaller volumes of the whole hippocampus (Cohen'sd = -0.20), cornu ammonis (CA)1 (d = -0.18), CA2/3 (d = -0.11), CA4 (d = -0.19), molecular layer (d = -0.21), granule cell layer of dentate gyrus (d = -0.21), hippocampal tail (d = -0.10), subiculum (d = -0.15), presubiculum (d = -0.18), and hippocampal amygdala transition area (d = -0.17) compared to HC. Lithium users did not show volume differences compared to HC, while non-users did. Antipsychotics or antiepileptic use was associated with smaller volumes. In this largest study of hippocampal subfields in BD to date, we show widespread reductions in nine of 12 subfields studied. The associations were modulated by medication use and specifically the lack of differences between lithium users and HC supports a possible protective role of lithium in BD.
AB - The hippocampus consists of anatomically and functionally distinct subfields that may be differentially involved in the pathophysiology of bipolar disorder (BD). Here we, the Enhancing NeuroImaging Genetics through Meta-Analysis Bipolar Disorder workinggroup, study hippocampal subfield volumetry in BD. T1-weighted magnetic resonance imaging scans from 4,698 individuals (BD = 1,472, healthy controls [HC] = 3,226) from 23 sites worldwide were processed with FreeSurfer. We used linear mixed-effects models and mega-analysis to investigate differences in hippocampal subfield volumes between BD and HC, followed by analyses of clinical characteristics and medication use. BD showed significantly smaller volumes of the whole hippocampus (Cohen'sd = -0.20), cornu ammonis (CA)1 (d = -0.18), CA2/3 (d = -0.11), CA4 (d = -0.19), molecular layer (d = -0.21), granule cell layer of dentate gyrus (d = -0.21), hippocampal tail (d = -0.10), subiculum (d = -0.15), presubiculum (d = -0.18), and hippocampal amygdala transition area (d = -0.17) compared to HC. Lithium users did not show volume differences compared to HC, while non-users did. Antipsychotics or antiepileptic use was associated with smaller volumes. In this largest study of hippocampal subfields in BD to date, we show widespread reductions in nine of 12 subfields studied. The associations were modulated by medication use and specifically the lack of differences between lithium users and HC supports a possible protective role of lithium in BD.
KW - ATLAS
KW - BRAIN
KW - CELL-PROLIFERATION
KW - DENTATE GYRUS
KW - HALOPERIDOL
KW - INTERNEURONS
KW - LITHIUM-TREATED PATIENTS
KW - MRI
KW - SCHIZOPHRENIA
KW - SEGMENTATION
KW - bipolar disorder subtype
KW - hippocampus
KW - large-scale
KW - lithium
KW - psychosis
KW - structural brain MRI
U2 - 10.1002/hbm.25249
DO - 10.1002/hbm.25249
M3 - Article
C2 - 33073925
SN - 1065-9471
VL - 43
SP - 385
EP - 398
JO - Human Brain Mapping
JF - Human Brain Mapping
IS - 1
ER -